
"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at docetaxel and saracatinib for prostate cancer that has continued to grow despite other treatment and has spread outside the prostate. This trial is supported by Cancer Research UK.
Doctors often treat prostate cancer that has spread with a chemotherapy drug called docetaxel (Taxotere). They hope that giving a new drug called saracatinib (also called AZD0530) as well as docetaxel will work better than docetaxel alone.
Saracatinib is a type of biological therapy called a tyrosine kinase inhibitor. Researchers hope that it will stop the cancer growing and spreading. But it is a new drug and they are not sure yet how well it work.
There is some evidence from other trials that saracatinib may also help with pain caused by prostate cancer that has spread. The people taking part in this trial will fill out questionnaires about their pain to help find out more about this.
The aims of this trial are to find out
You may be able to enter this trial if you
You cannot enter this trial if you
This is a phase 2 trial. It will recruit about 140 men with prostate cancer that has spread.
This is a randomised trial. The men taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in. This is called a double blind trial.
You have docetaxel through a drip into a vein once every 3 weeks. Each 3 weeks of treatment is called one cycle and you will have up to 10 cycles. Docetaxel is a standard treatment for this group of patients.
You will either take saracatinib or placebo tablets once every day, depending on which group you are in. You start taking the tablets 7 days before your first dose of docetaxel.
You will keep taking saracatinib or placebo tablets unless there are signs that your cancer has started to grow again, or you have serious side effects. If this happens you will stop and your doctor will discuss other treatment options with you.
If you agree to take part in this trial, the research team will ask you if they can take extra blood and urine samples to help them with their future research. If you don't want to give these samples, you don't have to. You can still take part in the trial.
You see the doctors and have some tests before you start treatment as part of this trial. The tests include
At the beginning of each 3 week cycle of treatment you fill out a questionnaire about any pain you are having.
You see the trial doctors once every 3 weeks while you are having treatment. You have a physical examination, blood tests (including a PSA test) and a urine test at each visit.
About a month after you finish treatment you have a CT or MRI scan, bone scan, chest X-ray, blood tests and urine test. You see the doctors and have a PSA test about every 6 weeks after that.
Saracatinib is a new drug so there may be side effects that the trial team don’t know about yet. Side effects we know about so far include
The most common side effects of docetaxel include
We have more information about the side effects of docetaxel in our Cancer drugs section.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Rob J Jones
AstraZeneca
Beatson Oncology Centre
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NHS Greater Glasgow and Clyde
NIHR Clinical Research Network: Cancer
University of Glasgow
This is Cancer Research UK trial number CRUKE/10/043.
Freephone 0808 800 4040
"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”